Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleLetters to the Editor

Rosuvastatin and Its Evolving Role as a Vascular Remodeling and Antiproliferative Agent in Different Systemic Malignancies

Shailendra Kapoor
Journal of Pharmacology and Experimental Therapeutics March 2017, 360 (3) 434; DOI: https://doi.org/10.1124/jpet.116.239400
Shailendra Kapoor
Private practice, Richmond, Virginia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Rosuvastatin (RST) modulates vascular remodeling in different systemic malignancies, thereby restricting tumor growth and expansion.

RST has an inhibitory effect on tumor growth in prostatic malignancies. This was confirmed by Lustman et al. (2014) in a recent study in which they reported a hazard ratio of 0.22. Prolonged use as well as higher doses both have a more pronounced effect in decreasing the risk of prostate cancer. Similarly, RST has a negative effect on tumor cell invasiveness as well as metastasis. Brown et al. (2012) have recently demonstrated that RST mediates this role in part by downregulating geranylgeranyl pyrophosphate production. These changes were recently confirmed in PC-3 cell lines. Similarly, RST exposure has a limiting effect on tumor growth in dermatological malignancies, especially malignant melanomas. Maj et al. (2016) have recently demonstrated that RST mediates this role by attenuating intratumoral proliferation. These changes are dose dependent and were recently confirmed in A375 as well as WM1552C cell lines.

RST also has a restricting effect on neoplastic expansion in hepatic malignancies. It mediates this role in part by modulating Notch4 expression. Tijeras-Raballand et al. (2010) have recently demonstrated that RST also has a negative effect on intratumoral angiogenesis. The number of smooth muscle actin–positive arteries is especially reduced. As a result, “survival time” is significantly prolonged. Not surprisingly, Chen et al. (2015) reported an odds ratio of 0.22 when analyzing the association between RST administration and the decreased risk of hepatocellular carcinoma in individuals with diabetes. The authors reported an odds ratio of 0.24 when RST was coadministered with metformin.

The above data were recently confirmed by Chen et al. (2016) in a recent study, in which they reported that RST especially has a marked chemopreventive effect against various cancers in patients with chronic obstructive pulmonary disease. The above examples further confirm the antineoplastic activity of RST in different systemic malignancies.

Footnotes

    • Received December 7, 2016.
    • Accepted December 22, 2016.
  • dx.doi.org/10.1124/jpet.116.239400.

Abbreviation

RST
rosuvastatin
  • Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Brown M,
    2. Hart C,
    3. Tawadros T,
    4. Ramani V,
    5. Sangar V,
    6. Lau M, and
    7. Clarke N
    (2012) The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer 106:1689–1696.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Chen CC,
    2. Hsu YP,
    3. Liu JC,
    4. Kao PF,
    5. Sung LC,
    6. Lin CF,
    7. Hao WR,
    8. Liu SH, and
    9. Wu SY
    (2016) Statins dose-dependently exert significant chemopreventive effects against various cancers in chronic obstructive pulmonary disease patients: a population-based cohort study. J Cancer 7:1892–1900.
    OpenUrl
  3. ↵
    1. Chen HH,
    2. Lin MC,
    3. Muo CH,
    4. Yeh SY,
    5. Sung FC, and
    6. Kao CH
    (2015) Combination therapy of metformin and statin may decrease hepatocellular carcinoma among diabetic patients in Asia. Medicine (Baltimore) 94:e1013.
    OpenUrl
  4. ↵
    1. Lustman A,
    2. Nakar S,
    3. Cohen AD, and
    4. Vinker S
    (2014) Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study. Prostate Cancer Prostatic Dis 17:6–9.
    OpenUrl
  5. ↵
    1. Maj M,
    2. Czajkowski R,
    3. Zegarska B,
    4. Kowaliszyn B,
    5. Pokrywczynska M, and
    6. Drewa T
    (2016) Anti-proliferative and cytotoxic activity of rosuvastatin against melanoma cells. Postepy Dermatol Alergol 33:257–262.
    OpenUrl
  6. ↵
    1. Tijeras-Raballand A,
    2. Hainaud-Hakim P,
    3. Contreres JO,
    4. Gest C,
    5. Le Henaff C,
    6. Levy BI,
    7. Pocard M,
    8. Soria C, and
    9. Dupuy E
    (2010) Rosuvastatin counteracts vessel arterialisation and sinusoid capillarisation, reduces tumour growth, and prolongs survival in murine hepatocellular carcinoma. Gastroenterol Res Pract 2010:640797.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 360 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 360, Issue 3
1 Mar 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Rosuvastatin and Its Evolving Role as a Vascular Remodeling and Antiproliferative Agent in Different Systemic Malignancies
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleLetters to the Editor

Letters to the Editor

Shailendra Kapoor
Journal of Pharmacology and Experimental Therapeutics March 1, 2017, 360 (3) 434; DOI: https://doi.org/10.1124/jpet.116.239400

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleLetters to the Editor

Letters to the Editor

Shailendra Kapoor
Journal of Pharmacology and Experimental Therapeutics March 1, 2017, 360 (3) 434; DOI: https://doi.org/10.1124/jpet.116.239400
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • Abbreviation
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Letters to the Editor
  • TDF is not an Inhibitor of OCT1
Show more LETTERS TO THE EDITOR

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics